ClinicalTrials.gg
RecruitingNCT06430554Updated Sep 3, 2026

Personalized Ventilation Based on Ventilation-perfusion Mismatch and Lung Recruitability

An observational study in Respiratory Distress Syndrome, Positive-Pressure Respiration and Mechanical Ventilation, sponsored by Zhongda Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by Zhongda Hospital · Observational

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
40
Ages
18 Years to 85 Years
Sex
All
01

Study summary

This observational study will explore the effects of PEEP and position on regional lung ventilation-perfusion mismatch by electrical impedance tomography (EIT) in moderate-to-severe ARDS patients with different lung recruitability.

Read the detailed description

Acute respiratory distress syndrome (ARDS) is characterized by impaired ventilation-perfusion matching, which not only indicates the severity of the condition but also contributes to ventilation-induced lung injury. Higher positive end-expiratory pressure (PEEP) and prone position could improve ventilation-perfusion mismatch by recruiting collapsed lungs and facilitating more homogeneous ventilation, but these benefits might depend on lung recruitability. The present study aims to elucidate the regional effect of PEEP(low and high) and body position(supine and prone) on the ventilation-perfusion matching. Also endeavors to establish correlations between alterations in ventilation-perfusion matching patterns and the inherent lung recruitability.

Participants will be deeply sedated and paralyzed, ventilated in volume-controlled with protective ventilation (tidal volume=6-8 mL/Kg of predicted body weight and respiratory rate set to obtain normal pH). Then the patients will be sequentially assigned to each of four conditions as follows:

Low PEEP, supine position; High PEEP, supine position; Low PEEP, prone position; High PEEP, prone position. High PEEP and low PEEP is defined as 15 cmH2O and 5 cmH2O (or airway opening pressure, either of which was higher) respectively. Each measurement (e.g., arterial blood gas analysis, respiratory parameters, hemodynamics, EIT measurements) will be performed at least 15 minutes after changing ventilator settings and at least 1 hour after changing body positions. The timing of turning patients from supine to prone position is determined by the clinical team.

To assess lung recruitability, a single-breath derecruitment maneuver will be performed by changing PEEP 15 to 5 cmH2O (or airway opening pressure, either of which was higher) in supine position. Patients with recruitment-inflation ratio over the median value are defined as high recruiters.

EIT data will be collected by standard device (Infinity C500, Drager, Germany) with a sample rate of 50 Hz. The EIT belt will be placed directly below the armpits, between the third and fifth intercostal spaces. This positioning of the EIT belt will be maintained consistently during both supine and prone positions. A bolus of 10 ml 5% NaCl will be injected during a respiratory pause (≥8 s) through the central venous catheter to assess lung ventilation and perfusion distributions. The primary endpoint is EIT-based ventilation-perfusion matching (V/Q match%).

02

Conditions studied

  • Respiratory Distress Syndrome
  • Positive-Pressure Respiration
  • Mechanical Ventilation

Keywords

  • Acute respiratory distress syndrome;Positive end expiratory pressure; Prone Position; Ventilation/perfusion matching.
03

In context

Respiratory Distress Syndrome

1,387 studies on the registry are indexed under Respiratory Distress Syndrome; 283 are open to participants now.

This study's planned enrollment of 40 is below the median of 100 across 475 observational studies indexed under Respiratory Distress Syndrome.

Browse Respiratory Distress Syndrome studies →

Lead sponsor

Zhongda Hospital is the lead sponsor of 104 studies on the registry; 42 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Intubated mechanically ventilated ARDS patients.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. age ≥18 years
  2. Moderate-to-severe ARDS as per the 2023 ESICM definition
  3. Undergoing invasive mechanical ventilation
  4. Planned prone position based on the attending physicians' decisions
  5. Signed

Exclusion criteria

Exclusion Criteria:

  1. age ≥85 years
  2. Pregnancy
  3. Severe hemodynamic instability (> 30% increase in vasopressors in the last 6 hours or norepinephrine > 0.5 µg/kg/min)
  4. Clinically suspected elevated intracranial pressure (>18 mm Hg)
  5. Bronchopleural fistula
  6. to EIT monitoring (e.g. burns, pacemaker, thoracic wounds limiting electrode belt placement)
  7. Severe hypernatremia (>170mmol/L)
  8. Re-admission of patients already enrolled in this study, or patients who are participating in other studies
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
40 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Ventilation-perfusion matching (V/Q match%)

    corresponding to the pixels that are both ventilated and perfused divided by the total number of pixels ventilated and/or perfused

    Time frame: Through study completion (within 24 hours)

Secondary outcomes

  1. percentage of dead space

    corresponding to the ventilated but nonperfused pixels divided by the total number of pixels ventilated and/or perfused

    Time frame: Through study completion (within 24 hours)

  2. percentage of shunt

    corresponding to the perfused but nonventilated pixels divided by the total number of pixels ventilated and/or perfused

    Time frame: Through study completion (within 24 hours)

  3. Respiratory system compliance

    The compliance of respiratory system

    Time frame: Through study completion (within 24 hours)

  4. PaO2/FiO2 ratio

    PaO2/FiO2 ratio

    Time frame: Through study completion (within 24 hours)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06430554
Lead sponsor
Zhongda Hospital
Responsible party
Fengmei Guo (Director of Intensive Care Unit, Principal Investigator, Clinical Professor, Zhongda Hospital, Southeast University, China, Zhongda Hospital) — Principal investigator
First posted
May 28, 2024
Start date
Jun 8, 2024
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Sep 3, 2026

Study contacts

Fengmei Guo, PhD, MD
Contact
fmguo2022@163.com
+8613813841261
Zhiqian Zha, MM
Contact
15505083904@163.com
+8615505083904
Fengmei Guo, PhD, MD
study chair · Nanjing Zhongda Hospital, Southeast University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion